Skip to main content
. 2011 Mar 9;117(21):5723–5732. doi: 10.1182/blood-2010-11-321398

Table 1.

Results of platelet count and IPF values for ITP patient episodes before and up to 10 days after therapeutic interventions

Treatment Platelet count, × 109/L
 Absolute IPF, × 109/L
 IPF, %
Pretreatment Maximum posttreatment Change* Pretreatment Maximum posttreatment Change* Pretreatment Maximum posttreatment Change*
Eltrombopag 13 113 100 7.4 66.4 59‖ 57.2 58.8 1.6
Eltrombopag 16 565 549 5.9 29.4 23.5‖ 36.6 5.2 −31.4
Eltrombopag 29 173 144 3.4 18.2 14.8‖ 11.6 10.5 −1.1
Eltrombopag 2 47 45 1.0 17.4 16.4‖ 52.2 37.1 −15.1
Eltrombopag 17 634 617 3.9 23.5 19.6‖ 22.8 3.7 −19.1
Placebo† 8 14 6 3.5 4.1 0.6 43.7 29.4 −14.3
GMA161 14 60 46 3.4 13 9.6 24.2 21.6 −2.6
GMA161 13 45 32 1.2 3.8 2.6 9.2 17.1 7.9
Anti-DX‡ 9 79 70 2 5.5 3.5 21.9 6.9 −15
Anti-DX‡ 14 115 101 2.2 2.8 0.6 15.8 2.4 −13.4
Anti-D 13 167 154 2 5 3 15.7 3 −12.7
Anti-DA§ 7 335 328 2.8 8.4 5.6 39.8 2.5 −37.3
Anti-DA§ 10 175 165 2.1 6.8 4.7 21.1 3.9 −17.2
Anti-D 20 163 143 1.8 5.2 3.4 9 3.2 −5.8
Anti-D 16 421 405 2.2 7.6 5.4 14 1.8 −12.2
Anti-D 9 108 99 2.4 5 2.6 26.7 4.6 −22.1
Anti-D 12 409 397 2.5 5.3 2.8 21.2 1.3 −19.9
Anti-D + IVIG 3 160 157 1.8 17.3 15.5‖ 60.9 10.8 −50.1
IVIGY‡ 1 121 120 0.7 33.5 32.8‖ 67.2 27.2 −40
IVIGY‡ 1 79 78 0.3 15.2 14.9‖ 26.2 19.2 −7
IVIGY‡ 1 73 72 0.3 18.4 18.1‖ 29.3 25.2 −4.1
IVIGB§ 1 210 209 0.4 12 11.6‖ 38.5 5.7 −32.8
IVIGB§ 11 197 186 2.8 16.7 13.9‖ 25.8 8.5 −17.3
IVIG 48 113 65 13 17.5 4.5 27 15.5 −11.5
IVIG 10 143 133 1.7 8 6.3 17.3 5.6 −11.7
IVIG 15 58 43 2.1 2.3 0.2 14 4 −10
IVIG 9 46 37 1.7 9.8 8.1 19 21.3 2.3
IVIG 15 159 144 4.3 5.4 1.1 28.9 3.4 −25.5
IVIG 7 171 164 1.5 6.0 4.5 21.3 3.5 −17.8
*

The change in the platelet count and IPF indicates the difference between that parameter on the day of treatment and on the day of maximum observed count after treatment.

†

This patient received placebo during the Eltrombopag/placebo randomized controlled study.

‡

Data were available for the same patient on multiple, consecutive treatment episodes with the same agent for patient X with anti-D and patient Y with IVIG.

§

Data were available for the same patient on multiple, consecutive treatment episodes with the same agent for patient A with anti-D and patient B with IVIG.

‖

Greater than 10 × 109/L increase in absolute IPF.